Table 1.
Demographics of the study participants (n = 69).
| Clinical parameters | |
|---|---|
| Age (years) | 71.1 ± 9.0 |
| Gender (male/female) | 66/3 |
| BMI (kg/m2) | 21.4 ± 3.8 |
| Smoking history (pack-year) | 67.6 ± 33.0 |
| GOLD stage (I/II/III/IV, n) | 12/27/25/5 |
| mMRC dyspnea scale (0/1/2/3/4, n) | 5/18/27/16/3 |
| COPD assessment test (n = 41) | 16.8 ± 7.6 |
| 6-min walk distance (n = 48) (m) | 386.1 ± 115.8 |
| Medications | |
| No respiratory medication, n (%) | 5 (7.2%) |
| LAMA or LABA alone, n (%) | 17 (24.6%) |
| LABA-LAMA combo, n (%) | 19 (27.5%) |
| ICS-LABA combo, n (%) | 9 (13.0%) |
| Triple combo, n (%) | 19 (27.5%) |
| Pulmonary function | |
| %VC (%) | 100.4 ± 18.4 |
| %FVC (%) | 95.2 ± 17.5 |
| FEV1 (L) | 1.35 ± 0.59 |
| FEV1/FVC (%) | 43.8 ± 13.4 |
| %FEV1 (%) | 60.2 ± 24.2 |
| DLco (%) | 65.9 ± 24.3 |
| Evaluation of skeletal muscle on CT (n = 56) | |
| PMCSA (cm2) | 25.9 ± 7.9 |
| ECMCSA (cm2) | 27.8 ± 6.2 |
BMI body mass index, GOLD global initiative for chronic obstructive lung disease, mMRC modified medical research council, COPD chronic obstructive pulmonary disease, LAMA long-acting muscarinic antagonist, LABA long acting β2 adrenergic agonist, ICS inhaled corticosteroid, VC vital capacity, FVC forced vital capacity, FEV1 forced expiratory volume in 1 s, DLco diffusing capacity of lung for carbon monoxide, PMCSA cross-sectional area of pectoralis muscles, ECMCSA cross-sectional area of erector spinae muscles. Data are presented as mean ± standard deviation.